In the present study, we further disclosed that DCLK1 contributes to the activation of EMT in EGFR-TKI-resistant cells, and silencing of DCLK1 sensitizes lung carcinoma cells to EGFR-TKI by reversing the EMT process. This evidence concerns the gene DCLK1 and lung carcinoma.